Recently launched biosimilars across markets have begun scaling up and will gather momentum through the year, particularly in the second half of FY27, the company’s top executive said
Biosimilar ramp-up to drive growth for Biocon in FY27
Recently launched biosimilars across markets have begun scaling up and will gather momentum through the year, particularly in the second half of FY27, the company’s top executive said
